ClinicalTrials.gg
Not yet recruitingNCT07729826Updated Oct 13, 2026

C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Lupus Nephritis Refractory to Standard Therapy

A Phase 2 interventional study of C-CAR168 in Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE) and Autoimmune Diseases, sponsored by AbelZeta Inc.. Not yet recruiting. Open to participants aged 14 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by AbelZeta Inc. · Phase 2, Interventional, and Treatment

Updated Oct 13, 2026Title changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
14 Years to 70 Years
Sex
All
01

Study summary

This Phase 2, multicenter, open-label study will evaluate the safety and efficacy of a single infusion of autologous anti-CD20/BCMA chimeric antigen receptor T cells (C-CAR168) following lymphodepleting chemotherapy in participants with refractory lupus nephritis who are not responding to standard therapy.

Approximately 50 participants will undergo leukapheresis, lymphodepletion with fludarabine and cyclophosphamide, and infusion of C-CAR168. Participants will be followed for 104 weeks (approximately 2 years) to evaluate renal response, safety, CAR T-cell persistence, pharmacokinetics/pharmacodynamics, and biomarkers. Long-term safety follow-up for gene therapy-related events will continue for up to 15 years following CAR T-cell infusion.

Read the detailed description

This is a global, multicenter, single-arm, open-label Phase 2 study evaluating C-CAR168, an autologous dual-targeted anti-CD20/BCMA CAR T-cell therapy, in participants with biopsy-confirmed refractory lupus nephritis who are not responding to standard therapy.

Participants will undergo screening, leukapheresis, manufacture of autologous C-CAR168, lymphodepleting chemotherapy consisting of fludarabine and cyclophosphamide, followed by a single intravenous infusion of C-CAR168.

The study begins with a safety run-in involving the first five participants. Following review by the Safety Monitoring Committee (SMC), enrollment of the remaining participants may proceed if predefined safety criteria are met.

Participants will be followed for 104 weeks after infusion for evaluation of efficacy, safety, pharmacokinetics, pharmacodynamics, immunologic biomarkers, and patient-reported outcomes. Participants will subsequently be invited to enroll in a separate long-term follow-up study for continued safety monitoring consistent with FDA recommendations for gene-modified cellular therapies.

02

Conditions studied

  • Lupus Nephritis (LN)
  • Systemic Lupus Erythematosus (SLE)
  • Autoimmune Diseases

Keywords

  • Lupus Nephritis
  • Systemic Lupus Erythematosus
  • CAR T
  • CAR-T Cell Therapy
  • CD20
  • BCMA
  • Autoimmune Disease
  • Cell Therapy
  • CAR-T
  • CAR-T Therapy
  • LN
  • SLE
  • CAR T-cell therapy
  • CAR T-cell
  • chimeric antigen receptor T-cell therapy
  • lupus
  • Lupus Nephritis (LN)
  • adolescent
03

In context

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

This study's planned enrollment of 50 is close to the median of 48 across 243 interventional studies indexed under Lupus Nephritis.

Browse Lupus Nephritis studies →

Lead sponsor

AbelZeta Inc. is the lead sponsor of 6 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to provide or assent where applicable.
  • Male or female aged 14-70 years, weighing at least 40 kg.
  • Diagnosis of systemic lupus erythematosus according to the 2019 EULAR/ACR classification criteria.
  • -confirmed ISN/RPS Class III or IV lupus nephritis, with or without Class V, within 6 months before screening.
  • Proteinuria meeting protocol-defined thresholds.
  • to standard therapy.
  • Meets taper requirements.
  • Positive ANA and/or anti-dsDNA and/or anti-Smith antibody.
  • Meets all protocol eligibility requirements.

Exclusion criteria

Exclusion Criteria:

  • Active uncontrolled infection
  • Active , , or infection
  • Active tuberculosis
  • Pregnancy or breastfeeding
  • Prior gene therapy or CAR T-cell therapy
  • Active
  • Severe cardiovascular disease
  • Significant pulmonary disease
  • CNS disease precluding participation
  • Any condition that would interfere with study participation or safety
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    C-CAR168

    Participants will receive: * Leukapheresis * Fludarabine * Cyclophosphamide * Single intravenous infusion of C-CAR168

    Drug: C-CAR168

Interventions

  • DrugC-CAR168

    Autologous anti-CD20/BCMA chimeric antigen receptor T-cell therapy administered as a single intravenous infusion at a target dose of 1 × 10\^6 CAR-positive T cells/kg (maximum dose 100 × 10\^6 CAR-positive T cells).

06

What researchers measure

Primary outcomes

  1. Complete Renal Response (CRR)

    Proportion of participants achieving Complete Renal Response according to protocol-defined criteria.

    Time frame: Week 65 (Month 15)

Secondary outcomes

  1. Incidence and severity of adverse events (AEs)

    Evaluate the incidence, severity, and relationship of adverse events following C-CAR168 infusion, graded according to NCI CTCAE Version 6.0.

    Time frame: Through Week 104 (Month 24)

  2. incidence of serious adverse events (SAEs)

    Evaluate the incidence of serious adverse events following treatment.

    Time frame: Through Week 104 (Month 24)

  3. Incidence and severity of cytokine release syndrome (CRS)

    Assess CRS according to American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading criteria.

    Time frame: Through Week 104 (Month 24)

  4. Incidence and severity of immune effector cell-associated neurotoxicity syndrome (ICANS)

    Assess ICANS according to ASTCT consensus grading criteria.

    Time frame: Through Week 104 (Month 24)

  5. Duration of Complete Renal Response (CRR)

    Evaluate the maintenance of complete renal response without relapse, flare, or rescue medication.

    Time frame: Through Week 104 (Month 24)

  6. Partial Renal Response (PRR)

    Evaluate the proportion of participants achieving partial renal response.

    Time frame: Through Week 104 (Month 24)

  7. Primary Efficacy Renal Response (PERR)

    Evaluate the proportion of participants achieving Primary Efficacy Renal Response.

    Time frame: Through Week 104 (Month 24)

  8. Reduction in proteinuria

    Evaluate the proportion of participants achieving at least a 75% reduction in urine protein-to-creatinine ratio (uPCR).

    Time frame: Through Week 104 (Month 24)

  9. Time to renal response

    Evaluate the time to achievement of Complete Renal Response, Partial Renal Response, and Primary Efficacy Renal Response.

    Time frame: Through Week 104 (Month 24)

  10. Pharmacokinetics of C-CAR168 measuring quantitative polymerase chain reaction (qPCR)

    Characterize CAR T-cell expansion and persistence using qPCR

    Time frame: Through Week 104 (Month 24)

  11. Pharmacokinetics of C-CAR168 utilizing flow cytometry

    Characterize T-cell expansion and persistence utilizing flow cytometry

    Time frame: Through Week 104 (Month 24)

  12. Change in patient-reported outcomes (PROs)

    Evaluate changes in health-related quality of life using PROs.

    Time frame: Through Week 104 (Month 24)

  13. DORIS remission

    Evaluate the proportion of participants achieving the Definition of Remission in SLE (DORIS).

    Time frame: Though Week 104 (Month 24)

  14. Progressive renal failure

    Evaluate the proportion of participants experiencing progressive renal failure as measured by estimated glomerular filtration rate (eGFR).

    Time frame: Through Week 104 (Month 24)

  15. Corticosteroid reduction

    Evaluate the proportion of participants receiving less than 5 mg/day prednisone equivalent.

    Time frame: Through Week 104 (Month 24)

  16. Lupus disease flare

    Evaluate the proportion of participants experiencing disease flare according to the SELENA-SLEDAI Flare Index.

    Time frame: Through Week 104 (Month 24)

  17. Immunologic response

    Evaluate changes in anti-double stranded DNA antibodies, circulating B cells, plasma cells, and complement C3/C4 levels.

    Time frame: Through Week 104 (Month 24)

Other outcomes

  1. Exploratory Biomarker Assessments

    Evaluate exploratory biomarkers associated with treatment with C-CAR168 and their relationship to efficacy and safety. Biomarkers include C-CAR168-related and disease-related markers in blood, urine, and optional tissue specimens, including immune cell populations, gene expression, cytokines, and urinary biomarkers.

    Time frame: Through Week 104 (Month 24)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Individual participant data collected during this study will not be made available to other researchers.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Dec 2028, 27 months later.

Of 33 phase 2 interventional studies under Lupus Nephritis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 57. This study's planned 27 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2026
First posted
Jul 28, 2026
StartEst.
Sep 30, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Sep 1, 2029
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Title
C-CAR168 CAR, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy for the Treatment of, in Participants With Lupus Nephritis Refractory to Standard Therapy
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Title C-CAR168 CAR, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy for the Treatment of, in Participants With Lupus Nephritis Refractory to Standard Therapy
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07729826
Lead sponsor
AbelZeta Inc.
Responsible party
Sponsor
First posted
Jul 28, 2026
Start date
Sep 30, 2026 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Sep 1, 2029 (estimated)
Last update
Oct 13, 2026

Study contacts

Kirstin Liechty
Contact
kirstin.liechty@abelzeta.com
240-552-5870
Nurat Quadri
Contact
clinicaltrials@abelzeta.com
240-552-5870
Scott Antonia, MD, PhD
principal investigator · Duke University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion